Healthcare
Live Price
Offline$0.055
+0.00% today
1Y Change
-18.70%
Window
Jun 20, 2025 → May 28, 2026
Coverage: 210 bars · Jun 20, 2025 → May 28, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
The Oncology Institute, Inc. (TOIIW) is a Healthcare stock with a market cap of $400.00M and listed on NASDAQ. The stock last traded around $0.06 and down 18.7% across the available one-year price window (Jun 20, 2025 → May 28, 2026). Baseline metrics include revenue growth of +27.8%, EPS growth of +23.9%, a dividend yield of 0.0%. What stands out right now is revenue +27.8%, EPS +23.9%, free cash flow +8.4% with operating margin -7.2% and ROIC -35.7%. Valuation is more restrained than many high-expectation growth names at price/sales 0.8. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines TOIIW price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TOIIW
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TOIIW Max Drawdown
-87.72%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TOIIW and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$203.0M
-19.6% YoY
FY Net Income
-$10.9M
-7288.8% YoY
Free Cash Flow
-$35.7M
+46.9% YoY
Revenue Growth
+27.8%
EPS Growth
+23.9%
Gross Margin
13.8%
Net Margin
-12.1%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 503M | 393M | 324M | 252M | 203M |
| Gross Profit | 69M | 54M | 60M | 52M | 41M |
| Operating Income | -36M | -60M | -77M | -82M | -46M |
| EBITDA | -29M | -54M | -54M | -68M | -42M |
| Net Income | -61M | -65M | -83M | 152K | -11M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 34M | 50M | 33M | 14M | 114M |
| Total Assets | 165M | 173M | 209M | 262M | 203M |
| Total Liabilities | 180M | 169M | 152M | 138M | 99M |
| Shareholder Equity | -16M | 4M | 57M | 123M | 104M |
| Total Debt | 104M | 123M | 120M | 108M | 183K |
| Net Debt | 70M | 73M | 86M | 94M | -114M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
33M
+47.1% YoY
Capital Expenditures
3M
+44.9% YoY
Free Cash Flow
36M
+46.9% YoY
Key ratios
Gross Margin
13.8%
Operating Margin
-7.2%
Net Margin
-12.1%
ROE
759.7%
Debt / Equity
-1.67x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.